Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088062 · ClinicalTrials.gov registry record · Phase 1
STA-5326 in Crohn's Disease Patients
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00088062: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00088062 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088062, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
Interventions
- DRUG STA-5326
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-02 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088062
The ClinicalTrials.gov registry entry for NCT00088062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-5326 is the first listed.
NCT00088062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088062 about?
NCT00088062 is a clinical study titled "STA-5326 in Crohn's Disease Patients". The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
What is the current status of trial NCT00088062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2004-02. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00088062?
The interventions under investigation include: STA-5326 (DRUG).
Who is sponsoring clinical trial NCT00088062?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.